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ABSTRACT
Objective: There is evidence showing that Gleason grading of prostatic adenocarcinoma is one of the most powerful
predictors of biological behavior and one of the most influential factors used to determine treatment for prostate cancer. The
aim of the current study was to compare the Gleason score for needle biopsy to the Gleason score for the correspondent
surgical specimen, find any possible difference in the biochemical (PSA) progression following surgery in upgraded cases,
correlate Gleason score in the specimens to several clinicopathologic variables, and compare outcomes between patients
with low-grade vs. high-grade Gleason and Gleason scores 3+4 vs. 4+3.
Materials and Methods: The study population consisted of 200 consecutive patients submitted to radical prostatectomy.
Biochemical progression was defined as PSA ≥ 0.2 ng/mL. Time to PSA progression was studied using the Kaplan-Meier
product-limit analysis.
Results: In 47.1% of the cases, there was an exact correlation and 40.6% of cases were underestimated in the biopsies. Half
of the tumors graded Gleason 6 at biopsy were Gleason score 7 at surgery. These upgraded tumors had outcomes similar to
tumors with Gleason score 7 in both biopsy and surgery. There was a positive correlation of high-grade Gleason score in the
surgical specimens to higher preoperative PSA, more extensive tumors, positive margins and more advanced pathologic
staging. Tumors with a Gleason score ≥ 7 have lower PSA progression-free survival vs. Gleason scores < 7. In this series,
there was no significant difference when comparing Gleason scores of 3+4 vs. 4+3.
Conclusions: The findings support the importance of Gleason grading for nomograms, which are used by clinicians to
counsel individual patients and help them make important decisions regarding their disease.
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INTRODUCTION
There is evidence showing that a Gleason
grading of prostatic adenocarcinoma is one of the most
powerful predictors of biological behavior and one of
the most influential factors used to determine treat-
ment for prostate cancer. The Gleason grading sys-
tem is the most commonly used grading system for
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prostate cancer in the United States and is gaining
worldwide acceptance. There are several unique as-
pects of the Gleason grading system including the fact
that is solely based on the architectural pattern and
that cytologic features are not factored in (1-3).
The aim of the current study report was: a)
to compare the Gleason score on needle biopsy to
the Gleason score in the correspondent surgical speci-
men; b) to find any possible difference in the bio-
chemical (PSA) progression following surgery in
upgraded cases; c) to correlate the Gleason score in
the surgical specimen with the variables: preopera-
tive serum PSA, tumor extent, positive surgical mar-
gins, and extraprostatic extension (pT3a and/or
pT3b); and, d) to compare biochemical (PSA) pro-
gression following surgery between patients with
Gleason low-grade vs. high-grade, and Gleason score
3+4 vs. 4+3.
MATERIAL AND METHODS
This retrospective study was based on 200
consecutive patients submitted to retropubic radical
prostatectomy from January 1997 to July 2004 at our
Institution. The Gleason score on all needle biopsies
(58.9% sextant biopsies and 41.1% extended biop-
sies) was compared to the Gleason score on the cor-
respondent surgical specimen by one senior patholo-
gist (AB). The mean and median cores for the ex-
tended biopsies were 9.3 and 8.5 respectively. The
Gleason score in the specimen was evaluated to find
any association with the variables: preoperative se-
rum PSA, tumor extent, positive margins, extraprostatic
extension (pT3a and / or pT3b), and biochemical
(PSA) progression following surgery.
The previously fixed surgical specimen was
weighed, measured and the entire surface inked. The
bladder neck and apical margins were amputated.
From each cone-shaped amputated margin, 8 frag-
ments were processed through perpendicular sections
relative to the margins. The rest of the prostate was
serially cut in transverse sections at 3 to 5 mm inter-
vals. The prostate slices were subdivided into quad-
rants and labeled to allow for reconstruction as whole-
mount sections. Blocks were embedded in paraffin,
cut at 6μm, and one section from each block was
stained with hematoxylin and eosin.
Presence of adenocarcinoma was diagnosed
according to the criteria of Mostofi & Price (1). The
diagnosis was based on invasion or architectural dis-
turbance. Histological grading was performed accord-
ing to the Gleason system (2). Prostatic carcinomas
with final score < 7 were considered low-grade; and,
with final score ≥ 7 were considered high-grade (3).
Extraprostatic extension was diagnosed according to
Bostwick & Montironi (4), whenever cancer was seen
in adipose tissue, and corresponds to pT3a in the 2002
TNM staging system (5). Seminal vesicle invasion
(pT3b) was defined as an invasion of the muscular
wall, as described by Epstein et al. (6). Tumor extent
was estimated by use of a point-count method (7).
Drawn on a sheet of paper, each quadrant of the whole
mount sections contained 8 equidistant points. During
the microscopic examination of the slides, the tumor
area was drawn on the correspondent quadrant seen
on the paper. At the end of the examination, the amount
of positive points represented an estimate of the tu-
mor extent.
The data were analyzed using the Mann-
Whitney test for comparison of independent samples
and Spearman’s coefficient of rank correlation to
evaluate the association of Gleason score with preop-
erative serum PSA and tumor extent. Time to bio-
chemical (PSA) progression-free survival was stud-
ied using the Kaplan-Meier product limit analysis; the
comparison between the groups was done using the
log-rank test. Biochemical progression was defined
as PSA ≥ 0.2 ng/mL according to recent recommen-
dation of the American Urological Association (8). P
value < 0.05 was considered statistically significant.
All statistical analyses were performed using Statistica
5.5 (StatSoft, Inc., Tulsa, OK, USA).
RESULTS
We compared the Gleason score on 187
needle biopsies with matched whole mounted radical
retropubic prostatectomy specimens. Twelve patients
without information about Gleason grade on needle
biopsy were excluded, as well as one patient without
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carcinoma in the prostatectomy specimen. There was
exact correlation in 47.1% of cases. The Gleason
grade was higher (underestimated in the biopsies) in
40.6% of cases and lower (overestimated in the biop-
sies) in 12.3% of cases. The distribution in biopsies
was 2.1%, 68.1%, 24.5% and 5.3% of cases for
Gleason score 2-5, 6, 7, and 8-10 respectively; in the
surgical specimens, distribution was 8.5%, 27.6%,
57.3%, and 6.5% for the same Gleason scores re-
spectively. From a total of 128 tumors with a Gleason
score 6 in the biopsy, 65/128 (50.8%) tumors were
Gleason score 7 in the surgical specimen. From a to-
tal of 46 tumors with Gleason score 7 in the biopsy,
36/46 (78.3%) tumors were also 7 in the surgical speci-
men.
The data were analyzed using Spearman’s
coefficient of rank correlation to evaluate the asso-
ciation of Gleason score in the surgical specimen with
preoperative serum PSA in 199 patients. One case
showing no carcinoma in the prostatectomy specimen
was excluded. The median value of preoperative PSA
was 10.46 ng/mL (range: 0.28 to 50 ng/mL). There
was a positive correlation, albeit weak, of high-grade
Gleason score in the surgical specimens to higher pre-
operative serum PSA (p = 0.032; r = 0.152).
The tumor extent in the surgical specimens
ranged from 1 to 225 positive points (mean 37.5 posi-
tive points). Twenty-eight cases were excluded from
the analysis because the point count method was not
conducted, including one patient without carcinoma in
the prostatectomy specimen. More extensive tumors
correlated with high-grade Gleason score in the sur-
gical specimens using Spearman’s coefficient of rank
correlation (p < 0.001; r = 0.524).
A total of 82 (41.2%) surgical specimens
showed positive margins and 54 (27.1%) extraprostatic
extension (pT3a and/or pT3b). There was statistically
significant correlation between high-grade Gleason
score and positive margins (p < 0.001) as well as
extraprostatic extension (p < 0.001) using the Mann
Whitney test. Only one case was excluded for this
analysis. The higher percentage of positive margins
(41.2%) versus extraprostatic extension (27.1%) may
have occurred because in surgical specimens with
positive margins but no extraprostatic extension the
resulting stage is pT2+ or pT2x according to Epstein
(9). This stage denotes that elsewhere the tumor is
organ confined, yet one cannot determine whether
there is extraprostatic extension in the region of inci-
sion into the prostate because the edge of the pros-
tate has been left in the patient.
For the analysis of time to biochemical pro-
gression, 14 patients without tests for serum PSA level
following radical prostatectomy were excluded. The
mean and median follow-up of our study (111 cen-
sored and 75 uncensored patients) was 30.3 and 25.5
months, respectively (range 1 to 99 months). During
the follow-up 75/186 (40.3%) patients developed bio-
chemical (PSA) progression.
Time of biochemical (PSA) progression-free
survival comparing 68 patients with Gleason score <
7 (low-grade) vs. 118 patients with Gleason score ≥ 7
(high-grade) in the surgical specimens was statisti-
cally significant (log-rank, p = 0.005) (Figure-1). At 5
years, the PSA progression-free survival rates were
73% and 35% for patients with low-grade and high-
grade Gleason score in the surgical specimens, re-
spectively.
Time of biochemical (PSA) progression-free
survival comparing 87 patients with Gleason score
3+4=7 vs. 19 patients with Gleason score 4+3=7 was
not statistically significant (log-rank, p = 0.193) (Fig-
ure-2). At 5 years, the PSA progression-free survival
rates were 37% and 32% for patients with Gleason
score 3+4=7 and Gleason score 4+3=7, respectively.
COMMENTS
There have been several studies correlating
core biopsy and radical prostatectomy Gleason grade
(10-13). Bostwick (12) found for Gleason score an
exact correlation in 35% of cases; in 40% of the cases
the score was higher; and, in 25% was lower in the
surgical specimen. Spires et al. (11) found an exact
agreement between biopsy and excision in 58%, higher
grade in 37.5% and lower grade in 4.5% of the cases.
Steinberg et al. (10) at the Johns Hopkins Hospital
found an exact agreement of 58%. In our study the
exact agreement of Gleason score was 47.1%.
Gleason score was higher (underestimated on the bi-
opsies) in 40.6% of cases and lower (overestimated
26
Gleason Grading System as Predictor Factor
Figure 1 – Time to biochemical (PSA) progression-free survival comparing low-grade (group 0) vs. high-grade (group 1) Gleason score
in the surgical specimen. Kaplan-Meier product-limit analysis.
Figure 2 – Time to biochemical (PSA) progression-free survival comparing Gleason 3+4 (group 0) vs. Gleason 4+3 (group 1) in the
surgical specimen. Kaplan-Meier product-limit analysis.
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on the biopsies) in 12.3% of cases. In our series, half
of tumors graded Gleason score 6 at biopsy were
Gleason score 7 at surgery. This finding is similar to
the study by Pinthus et al. (13). We also compared
the PSA progression-free survival of tumors that were
scored 6 on prostate biopsy but were 7 on subsequent
radical prostatectomy to those in tumors with a con-
sistent rating of Gleason score 7 at biopsy and sur-
gery. Upgraded Gleason score 6 to 7 tumors had out-
come similar to those of Gleason score 7 in both bi-
opsy and surgical specimen (log-rank, p = 0.359). This
finding is also similar to the study by Pinthus et al.
(13).
For a low-grade Gleason score in biopsies,
urologists should consider the likelihood of tumor up-
grading when contemplating treatments. High-grade
Gleason score in biopsies have a high predictive value,
which is enhanced when combined with other clinical
parameters (14). Nomograms typically include the
Gleason score in the pretreatment variables. Based
on statistical modeling of cumulative, prospectively
accrued data from a large consecutive series of pa-
tients, the nomograms have a reasonable discrimina-
tory ability to counsel the urologist for pretreatment
bone scans, magnetic resonance imaging for seminal
vesicle involvement, and for lymph node dissection.
In general, serum PSA levels correlate with
larger tumor volume, advanced pathologic stages, and
higher grades. Although higher grade cancer produces
less PSA per cell as compared to lower grade tumors,
overall, poorly differentiated tumors are associated
with higher PSA levels as these tumors tend to be
larger and of more advanced stage (15). In our study,
there was a positive correlation, albeit weak, of high-
grade Gleason score in the surgical specimens to higher
preoperative serum PSA.
Many studies have been published that con-
sistently demonstrate the independent value of biopsy
Gleason score in predicting pathologic stage at radi-
cal prostatectomy (16,17). Based on these studies of
needle biopsies and radical prostatectomy specimens,
several groups have developed nomograms for pre-
dicting pathologic stage based on clinical stage, se-
rum prostate-specific antigen (PSA), and needle bi-
opsy Gleason score (18). The power of Gleason score
in predicting outcome after radical prostatectomy has
been repeatedly demonstrated in numerous reports
(19,20). Nomograms using the radical prostatectomy
Gleason score and other variables are widely avail-
able. In patients with organ-confined, margin-nega-
tive tumors, the data are particularly compelling. Pa-
tients with Gleason score 6 tumors infrequently fail
(21). Clinicians can use these nomograms to counsel
individual patients and help them make important de-
cisions regarding their disease. The findings of our
study support the importance of Gleason grading in
these nomograms. There was a statistically signifi-
cant correlation between high-grade Gleason score
and positive margins (p < 0.001) as well as
extraprostatic extension (p < 0.001) using the Mann-
Whitney test.
During the follow-up 75/186 (40.3%) patients
developed biochemical (PSA) progression. This rela-
tively high biochemical recurrence rate for our series
may be due to considering a prostate specific antigen
of > or = 0.2 ng/mL as a biochemical recurrence, based
on recent recommendations from the American Uro-
logical Association Prostate Guidelines (8). Accord-
ing to the Panel, strict definitions for biochemical re-
currence are necessary to identify men at risk, but
not necessarily to identify disease progression. The
purpose for establishing this standard is for data re-
porting purposes. It is not intended to represent thresh-
old value for initiating treatment. The Panel acknowl-
edges that the clinical decision to initiate treatment
will be dependent on multiple factors.
Time of biochemical (PSA) progression-free
survival comparing patients with Gleason score< 7
(low-grade) vs. Gleason score ≥ 7 (high-grade) was
statistically significant (log-rank, p = 0.005). At 5 years,
the PSA progression-free survival rates were 73%
and 35% for patients with low-grade and high-grade
Gleason score, respectively. These PSA progression-
free survival rates were independent of margin sta-
tus. Considering only patients with negative margins,
the biochemical progression-free survival was 41%
and 81% for high-grade and low-grade Gleason score,
respectively (log-rank, p = 0.019). For patients with
prostate cancer, the Gleason score remains one of
the most important parameters, affecting all aspects
of their disease to include, potentially, the therapeutic
stratification or approach. The importance placed by
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clinicians and patients on the many nomograms avail-
able cannot be overemphasized.
Tumors with a Gleason score of 7 have a sig-
nificantly worse prognosis than those with a Gleason
score of 6. Given the adverse prognosis associated
with Gleason pattern 4, one would expect that whether
a tumor is Gleason score 3+4 or 4+3 would influence
prognosis (9). This issue has been controversial in the
literature. No significant survival advantage was re-
ported for Gleason pattern 3+4 over 4+3 by Oefelein
et al. (22). Other investigators have shown that
Gleason score 4+3 has a worse prognosis than Gleason
score 3+4 (23,24). Chan et al. (24) found that the 5-
year actuarial risk of progression was 15% and 40%
for Gleason score 3+4 and 4+3 tumors respectively.
In our study, time of biochemical (PSA) progression-
free survival comparing patients with Gleason score
3+4=7 vs. Gleason score 4+3=7 was not statistically
significant (log-rank, p = 0.193). At 5 years, the PSA
progression-free survival rates were 37% and 32%
for patients with Gleason score 3+4=7 and Gleason
score 4+3=7, respectively. We must consider, how-
ever, that this series has small numbers and short fol-
low-up for any definitive conclusion to be drawn.
CONCLUSIONS
High-grade Gleason score tumors in the sur-
gical specimens show a positive correlation with higher
preoperative serum PSA, more extensive tumors, posi-
tive margins, and more advanced pathologic staging.
Most of the patients show either an exact Gleason
score or a higher score in the surgical specimen in
comparison to the biopsy. Half of tumors graded
Gleason score 6 at biopsy were Gleason score 7 at
surgery. Time of biochemical (PSA) progression-free
survival following surgery is significantly shorter for
patients with high-grade Gleason score in the surgical
specimens. Upgraded Gleason score 6 tumors in the
biopsy to 7 in surgery, have outcomes similar to those
of tumors with Gleason score 7 in both biopsy and
surgery. In our series, time of biochemical (PSA) pro-
gression-free survival between patients with Gleason
score 3+4 vs. 4+3 was not statistically significant. The
findings support the importance of Gleason grading
for nomograms, which are used by clinicians to coun-
sel individual patients and help them make important
decisions regarding their disease. Thus, accurate
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